Skip to main content

Evolving Landscape of US Food and Drug Administration Drug Approval in the Era of Precision Oncology: Finding the Right Balance Between Access and Safety.

Publication ,  Journal Article
Kuderer, NM; Lyman, GH
Published in: J Clin Oncol
June 20, 2018

Duke Scholars

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

June 20, 2018

Volume

36

Issue

18

Start / End Page

1773 / 1776

Location

United States

Related Subject Headings

  • United States Food and Drug Administration
  • United States
  • Randomized Controlled Trials as Topic
  • Precision Medicine
  • Oncology & Carcinogenesis
  • Neoplasms
  • Humans
  • Drug Approval
  • Antineoplastic Agents
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kuderer, N. M., & Lyman, G. H. (2018). Evolving Landscape of US Food and Drug Administration Drug Approval in the Era of Precision Oncology: Finding the Right Balance Between Access and Safety. J Clin Oncol, 36(18), 1773–1776. https://doi.org/10.1200/JCO.2018.78.5592
Kuderer, Nicole M., and Gary H. Lyman. “Evolving Landscape of US Food and Drug Administration Drug Approval in the Era of Precision Oncology: Finding the Right Balance Between Access and Safety.J Clin Oncol 36, no. 18 (June 20, 2018): 1773–76. https://doi.org/10.1200/JCO.2018.78.5592.
Kuderer, Nicole M., and Gary H. Lyman. “Evolving Landscape of US Food and Drug Administration Drug Approval in the Era of Precision Oncology: Finding the Right Balance Between Access and Safety.J Clin Oncol, vol. 36, no. 18, June 2018, pp. 1773–76. Pubmed, doi:10.1200/JCO.2018.78.5592.

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

June 20, 2018

Volume

36

Issue

18

Start / End Page

1773 / 1776

Location

United States

Related Subject Headings

  • United States Food and Drug Administration
  • United States
  • Randomized Controlled Trials as Topic
  • Precision Medicine
  • Oncology & Carcinogenesis
  • Neoplasms
  • Humans
  • Drug Approval
  • Antineoplastic Agents
  • 3211 Oncology and carcinogenesis